Company news

Tonix Pharmaceuticals Holding Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders

July 20, 2020

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

July 15, 2020

Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering

July 14, 2020

Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering

July 12, 2020

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

July 9, 2020

Tonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics

July 6, 2020

Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule

June 28, 2020

Tonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020

June 21, 2020

Tonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration

June 17, 2020

Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020

June 16, 2020

Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License

June 10, 2020

Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors

June 9, 2020

Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800

May 31, 2020

Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine

May 18, 2020

Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

May 11, 2020

Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19

May 6, 2020

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

April 23, 2020

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 23, 2020

Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering

March 2, 2020

Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market

February 27, 2020

Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)

February 25, 2020

Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering

February 10, 2020

Tonix Pharmaceuticals Prices $7.5 million Public Offering

February 6, 2020

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

February 4, 2020

Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

January 23, 2020

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

December 15, 2019

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

December 10, 2019

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

December 9, 2019

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 2, 2019

Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

November 25, 2019

Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

November 20, 2019

Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

November 19, 2019

Tonix Pharmaceuticals Prices $9.0 Million Public Offering

November 14, 2019

Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

November 7, 2019

Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

November 3, 2019

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

October 30, 2019

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

October 22, 2019

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

October 14, 2019

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

October 6, 2019

Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

October 2, 2019

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

September 15, 2019

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 3, 2019

← Newer news releases

Calls

Decks

The 5 newest of 284 decks. Every deck is listed under its year.